



COPY OF PAPERS  
ORIGINALLY FILED

1632

IN THE UNITED STATES PATENT AND TRADEMARK OFFICE

RECEIVED

APPLICANT: Price, et al

ART UNIT:  
1632

MAY 23 2002

FILED: June 14, 2001

EXAMINER:  
Ton, T.

TECH CENTER 1600/290

SERIAL NO.: 09/881,635

DOCKET: D6302

5-29-02  
P.L.

FOR: Regulation of the P21 Gene and  
Uses Thereof

The Honorable Commissioner of Patents  
BOX NON-FEE AMENDMENT  
Washington, DC 20231

**RESPONSE TO RESTRICTION REQUIREMENT AND**  
**CERTIFICATE OF MAILING UNDER 37 C.F.R. 1.8**

Dear Sir:

Responsive to the Restriction Requirement mailed April 26, 2002, Applicants elect Group I, claims 1-10, drawn to a method for treating or preventing a pathophysiological state of an organ in an individual, wherein said state is characterized by an undesirable level of cyclin-dependent kinase inhibitor activity in said organ, comprising the step of eliminating or reducing the expression of the *p21* gene in said organ of said individual, comprising using drug therapy, without traverse.

I hereby certify under 37 CFR 1.8 that the following correspondence is being deposited with the United States Postal Service as first class mail with sufficient postage on the date indicated below and is addressed to Honorable Commissioner for Patents, Box Non-Fee Amendment, Washington DC 20231. Please return the enclosed postcard acknowledging receipt of this correspondence.

Respectfully submitted,

Benjamin Aaron Adler, Ph.D., J.D.  
Registration No. 35,423  
Counsel for Applicant

Date: May 9, 2002

ADLER & ASSOCIATES  
8011 Candle Lane  
Houston, Texas 77071  
(713) 270-5391  
BADLER1@houston.rr.com